Antibiotics are powerful therapeutic agents that are produced by diverse living organisms. Over the last several decades, natural bioactive products particularly antibiotics have continued to play a significant role in drug discovery and has expanded the process for developing drugs with high degree of therapeutic index and specific action. Today, there is an alarming deficiency of new antibiotics in the pharmaceutical industry that could be due to the emergence of antibiotic resistance properties of some pathogens, toxicity and undesirable side effects of some used antibiotics. Although much progress has been performed in the field of chemical synthesis and engineered biosynthesis of antimicrobial compounds. Hence, there is a need in approach for novel antibiotics and research to improve the safety as well as therapeutic efficiency of the discovered bioactive compounds as part of the strategy to control the emerging drug-resistant pathogens in research programme around the world. This article reviews the history of antibiotics, different types of antibiotics, mechanisms of antibiotic action and new challenges in antibiotics.
INTRODUCTION
Antibiotics are the most important class of natural bioactive compounds (as a secondary metabolites) with low molecular weight (MW 3000) which are produced by or derived from diverse organisms (bacteria, actinomycetes, fungi, algae, lichens, green plants, etc.) by fermentation, which have the capacity of inhibiting or terminating total metabolic cell activity [1] [2] [3] . The word antibiotic came from the Greek word antibiosis (Gr. anti, "against"; bios, "life") a term coined by Louis Pasteur's pupil Paul Vuillemin in 1889.
They are defined as a chemical substance that either inhibits the growth of or destroys microorganisms. These natural compounds can show either antimicrobial (antibacterial, antifungal, antiprotozoal), antiviral and antitumor activities. They considered as 'bioactive compounds' because they have biological activity. Antimicrobial compounds are classified based on the range of effectiveness in to broad spectrum that are (effective against many types of microorganism) and narrow spectrum (effective against a limited group of microorganism) [1] . Antibiotics have been used in a variety of industries such as pharmaceuticals [4] and food industry , especially in the field of prebiotics and probiotics [3, 5] . This review outlines the history of antibiotics, different types of antibiotics, the mechanism of antibiotics action and new challenges in antibiotics.
HISTORY OF ANTIBIOTICS
Since the beginning of human suffering from infectious diseases caused by microorganisms, the search for solutions started and leads to discover of wide range of antibiotics from microorganisms such as actinomycetes [6, 7] . Thus, the microorganisms have made prominent contributions to the health and well-being of people throughout the world [8, 9] .
Although penicillin was the first antibiotic, discovered by Alexander Fleming in 1928, but it was not until the early 1940s that its true potential was acknowledged and large scale fermentation processes were developed for the production of antibiotics. Waksman and Schatz (1945) isolated streptomycin as a first aminoglycoside against tuberculosis and a number of other antibiotics from Streptomyces griseus [10, 11] . After the revolution in the "heroic" or "golden era", in the forties and early fifties, when nearly all groups of important antibacterial antibiotics (tetracyclines, cephalosporins, aminoglycosides, and macrolides) were discovered, the story of successfully continued [12] . It seemed that in the fifties and sixties that the main problems of chemotherapy had been solved. During this period the N. Khandan Dezfully et al. J Fundam Appl Sci. 2016, 8(2S) , 674-684 676 discovery of antitumor [13] , antiviral and non antibiotic enzyme inhibitory metabolites [14, 15] had just started [16] .
In the next period, between seventies and nineties the efficiency of research had had opened [16, 21] .
The number of antibiotics were known in 1940 about 10~20, in 1950, 300~400, already 800~1000 in 1960 and approximately 2500 till 1970. Since then the number of all known bioactive microbial metabolites had doubled in every ten years. In 1980 about 5,000 and in 1990 about 10,000 antibiotic compounds were known [16] . The results of an extensive research revealed that the total number of antibiotic compounds, recognized until now, is around 25,000~ 30,000 ( Figure 1 ). 
Classification of antibiotics
The great number of diverse antibiotics can be classified in different ways based on microbial spectrum, the type of biological activity and the chemical structure. But they are usually classified based on their structure and/or function [ 1, 3, 23] . 
Mechanism of antibiotic action
Antimicrobial agents are broadly classified based on in vitro behavior as microcidal (kill microorganisms directly) or microstatic (simply prevent them from growth). The major modes of action by different antibiotics include [1, 23]:
1) Inhibition of Cell wall synthesis
The antibiotics such as ß-lactams (penicillin, cephalosporins) and glycopeptides (vancomycine and teicoplanin) block the ability of bacteria to synthesize their cell wall by inhibiting the synthesis of peptidoglycan.
2) Plasma membrane inhibition
Certain antibiotics, especially polypeptide antibiotics, bring about changes in the permeability of the plasma membrane; these changes result in the loss of important metabolites from the microbial cell. As for example polymixin B binds to the phospholipids of the cell membrane and disrupts its integrity, destroying their ability to function as osmotic barriers.
3) Inhibition of nucleic acid synthesis
A number of antibiotics interfere with nucleic acid metabolism of microorganisms.
ciprofloxacine, nalidixic acid, rifamycin, trimethoprime, oxolinic acid, etc. bind to DNA gyrase (topoisomerase) thereby preventing the supercoiling of DNA, and inhibiting DNA synthesis. They are widely used in chemotherapy because they are more selective toxicity.
4) Inhibition of protein synthesis
The ribosomes are the sites of protein synthesis in the bacterial cell. Prokaryotic cells have 70S ribosome which is made up 50S and 30S unit. Antibiotics such as streptomycin , gentamycin, kanamycine, tetracycline, spectinomycine, chloramphenicol, and erythromycin bind to either 50S or 30S subunit of the ribosome or to mRNA and impair the functioning.There by inhibiting the synthesis of proteins.
5) Inhibition of enzymatic activity
Sulfonamides completely inhibit the important metabolic pathways (synthesis of folic acid)occurring inside the bacterial cell. Thus, important metabolites like folic acid, a vitamin that functions as a coenzyme for the synthesis of the purine and pyrimidine base of N. Khandan Dezfully et al. J Fundam Appl Sci. 2016, 8(2S) , 674-684 679 nucleic acids,which the bacteria have to produce within their cells to survive are not produced.
DRUG RESISTANCE IN MICROBES
Although, antimicrobial agents represent one of the essential therapeutic tools, both in human and veterinary medicine to control and treat a variety of microbial infectious diseases.
However, during the past five decades the use and sometimes misuse of antimicrobials has caused bacterial resistance to currently available antibacterial drugs by either new mutations or the exchange of genetic information that is, placing past resistance genes into new hosts [24] .
Several mechanisms of antimicrobial resistance are easily spread to a variety of bacterial genera [25, 26] : 
NEW CHALLENGES IN ANTIBIOTICS
Today, over 30,000 clinical diseases described. Under a third of these could be treated symptomicaly and just a few can be cured. Despite the developments and progress made in modern medicine, science and biotechnology, infectious diseases are still the second leading cause of death worldwide [27, 28] . It is an epidemic of multiple antibiotic resistance in pathogens has been described in various fields, including but not limited to a global pandemic of methicillin-resistant Staphylococcus aureus (MRSA) infection [29] . given effect and significant impact on morbidity and mortality, which has become a major clinical and public health problem in the 21st century [30] [31] [32] . According to World Health Organization (WHO), over-prescription and incorrect use of antibiotics leads to the generation of antibiotic resistance in many human pathogens. The slogan of WHO in 2011 was "multi-drug resistant pathogens have become a major global healthcare threat" [21] . Moreover, the undesirable side effects and toxicity of some used antibiotics (Ningthoujam et al, 2009), non-cultivable of some species of potent bacteria [33] and the exhaustion of the natural sources dictate an increasing necessity of survey for unexplored and under-explored niche habitats for the isolation and discovery of natural product-based drugs with broad-spectrum which possess different mechanisms of action and which are free from undesirable side effects (safe) [24] Such things be developed as part of the strategy to control the emerging drug-resistant pathogens in research programs around the world [32, [34] [35] [36] . Hence, there is a need for more and more screening programs in isolation of new potent organisms and novel antimicrobial metabolites from newer ecosystem for potential pharmaceutical, agriculture and industrial applications around the world [37] [38] [39] [40] [41] [42] [43] [44] [45] .
CONCLUSION
Antibiotics are secondary metabolites with powerful therapeutic activity which are produced by potent living organisms. In recent times, the drug resistant strains of microorganisms emerge more quickly than the rate of discovery of new drugs and antibiotics. Hence the search for isolating novel antibiotics continues to be of immense importance in research programs around the world for pharmaceutical, industrial and agricultural applications.
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